The PTH (1-84)/non-PTH (1-84) ratio is a risk factor for cardiovascular events in hemodialysis patients

被引:8
作者
Zitt, E. [2 ,3 ]
Kirsch, A. H.
Haueis, M.
Strasak, A. [4 ]
Neyer, U. [2 ,3 ]
Mayer, G.
Rosenkranz, A. R. [1 ]
机构
[1] Med Univ Innsbruck, Univ Klin Innere Med 4, Dept Internal Med 4, A-6020 Innsbruck, Austria
[2] Acad Teaching Hosp Feldkirch, Dept Nephrol & Dialysis, Feldkirch, Austria
[3] VIVIT, Feldkirch, Austria
[4] Med Univ Innsbruck, Dept Med Stat, A-6020 Innsbruck, Austria
关键词
PTH; secondary hyperparathyroidism; PTH (1-84)/non-PTH (1-84) ratio; cardiovascular morbidity; cardiovascular mortality; hemodialysis; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; PARATHYROID-HORMONE ASSAYS; INCIDENT DIALYSIS PATIENTS; ALL-CAUSE MORTALITY; VASCULAR CALCIFICATION; BONE HISTOMORPHOMETRY; MINERAL METABOLISM; SERUM-CALCIUM; ASSOCIATION;
D O I
10.5414/CNP75309
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: We hypothesized that the PTH (1-84)/non-PTH (1-84) ratio (PTH ratio) might help to assess cardiovascular risk in hemodialysis patients. Methods: In this prospective cohort study 70 prevalent hemodialysis patients were followed up to 4 years. The PTH ratio was determined at base-line. Primary outcomes were cardiovascular events (CV E) and all-cause mortality. Cumulative event-free survival was compared between patients with a ratio < 1 and those with a ratio > 1. The risk-association of the PTH ratio with CVE was examined using an adjusted Multiple Cox Proportional Hazards model. Results: A PTH ratio > 1 was found in 34 patients (49%). During follow-up 26 patients suffered a CVE. Patients with a CVE showed a higher ratio than patients with event-free survival (p = 0.033). In patients with a ratio > 1 a significantly higher number of CVE occurred (53 vs. 22%; p = 0.013), and these patients showed a significantly shorter event-free survival (p = 0.032). In an adjusted Cox-proportional hazards model a higher PTH ratio was found to be independently associated with an elevated risk for CVE (HR = 3.2; 95% Cl 1.06 - 13.63; p = 0.04). Conclusions: A higher PTH (1-84)/non-PTH (1-84) ratio is associated with an increased risk for CVE in hemodialysis patients and might therefore be useful for cardiovascular risk estimation in this population.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 50 条
  • [31] Significance of Bio-intact PTH(1–84) assay in hemodialysis patients
    Masaaki Inaba
    Senji Okuno
    Yasuo Imanishi
    Misako Ueda
    Tomoyuki Yamakawa
    Eiji Ishimura
    Yoshiki Nishizawa
    Osteoporosis International, 2005, 16 : 517 - 525
  • [32] The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD)
    O'Flaherty, D.
    Sankaralingam, A.
    Scully, P.
    Manghat, P.
    Goldsmith, D.
    Hampson, G.
    CLINICAL BIOCHEMISTRY, 2013, 46 (15) : 1405 - 1409
  • [33] Comparison of the Elecsys PTH(1-84) assay with four contemporary second generation intact PTH assays and association with other biomarkers in chronic kidney disease patients
    Tan, Karen
    Ong, Lizhen
    Sethi, Sunil K.
    Saw, Sharon
    CLINICAL BIOCHEMISTRY, 2013, 46 (09) : 781 - 786
  • [34] Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients
    Tomida, Kodo
    Hamano, Takayuki
    Mikami, Satoshi
    Fuji, Naohiko
    Okada, Noriyuki
    Matsui, Isao
    Nagasawa, Yasuyuki
    Moriyama, Toshiki
    Ito, Takahito
    Imai, Enyu
    Isaka, Yoshitaka
    Rakugi, Hiromi
    BONE, 2009, 44 (04) : 678 - 683
  • [35] Vasodilation to PTH (1-84) in bone arteries is dependent upon the vascular endothelium and is mediated partially via VEGF signaling
    Prisby, Rhonda
    Menezes, Thomas
    Campbell, Jeremiah
    BONE, 2013, 54 (01) : 68 - 75
  • [36] Factors related to bone forming inadequate response to treatment (teriparatide/PTH 1-84) in patients with severe osteoporosis. Preliminary results
    Gifre, L.
    Monegal, A.
    Filella, X.
    Muxi, A.
    Guanabens, N.
    Peris, P.
    REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL, 2015, 7 (04) : 85 - 90
  • [37] PTH(1-84) Replacement Therapy in Hypoparathyroidism: A Randomized Controlled Trial on Pharmacokinetic and Dynamic Effects After 6 Months of Treatment
    Sikjaer, Tanja
    Amstrup, Anne Kristine
    Rolighed, Lars
    Kjaer, Soren Geill
    Mosekilde, Leif
    Rejnmark, Lars
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (10) : 2232 - 2243
  • [38] Absence of adynamic bone disease in African-Americans with CKD Stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio
    Fehmi, H.
    Osman, Y.
    Bhat, S.
    Nguyen, K.
    Daramola, O.
    Cantor, T.
    Monier-Faugere, M. -C.
    Yee, J.
    Malluche, H. H.
    CLINICAL NEPHROLOGY, 2009, 71 (03) : 267 - 275
  • [39] Amino terminal cleavage of PTH(1–84) to PTH(7–84) is regulated by serum calcium concentration via calcium-sensing receptor in hemodialysis patients
    Masao Koshikawa
    Kensuke Nishiguchi
    Soshi Yorifuji
    Keiji Shimazu
    Koji Takaori
    Keita Mori
    Eriko Eguchi
    Kikuo Okada
    Atsuo Tanaka
    Takashi Kuwahara
    Clinical and Experimental Nephrology, 2010, 14 : 233 - 238
  • [40] Increased active PTH(1–84) fraction as a predictor of poor mortality in male hemodialysis patients
    M. Inaba
    S. Okuno
    Y. Imanishi
    E. Ishimura
    T. Yamakawa
    S. Shoji
    Osteoporosis International, 2013, 24 : 2863 - 2870